OOIR: Observatory of International Research

Papers

(The median citation count of JAMA Neurology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Diplopia and Ptosis in an Older Woman	472
Somebody to Love	450
Early Posttraumatic Seizures—Putting Things in Perspective	437
Optimizing the Time Course of Risks and Benefits of Acute Dual Antiplatelet Therapy for Stroke Prevention	385
Substantia Nigra Pathology, Contact Sports Play, and Parkinsonism in Chronic Traumatic Encephalopathy	353
Equipping AI for Unbiased and Inclusive Neurology	342
Itching Frequency and Neuroanatomic Correlates in Frontotemporal Lobar Degeneration	222
Error in Author Name	220
Rizatriptan vs Placebo for Attacks of Vestibular Migraine	219
Origin of Transthyretin in Cerebral Amyloid Angiopathy	216
Association Between Increased Seizures During Rewarming After Hypothermia for Neonatal Hypoxic Ischemic Encephalopathy and Abnormal Neurodevelopmental Outcomes at 2-Year Follow-up	212
Automated Imaging Differentiation for Parkinsonism	204
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation	199
Ghrelin for Neuroprotection in Post–Cardiac Arrest Coma	198
Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis	198
Early Access to First-Seizure Clinics, Subsequent Outcomes, and Factors Associated With Attendance	196
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation	187
Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis	182
A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials	176
Alternate Hemibody Hyperkinetic and Hypokinetic Movement Disorders Due to Strategic Lesions in Cerebral Toxoplasmosis	176
Magnetic Resonance Imaging Features of Tropical Candidal Meningoencephalitis	173
Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach	165
JAMA Neurology	165
JAMA Neurology	165
Is It Really Itching?	150

The Neurologist’s Imperative in Brain Death	149
Teleneurorehabilitation and Motor and Nonmotor Symptoms and Quality of Life in Parkinson Disease	146
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis	142
Time to Change the Current Clinical Classification of Multiple Sclerosis?	139
Time From Hospital Arrival Until Endovascular Thrombectomy and Patient-Reported Outcomes in Acute Ischemic Stroke	134
Anticoagulation and Antiplatelet Therapy in Patients With Atrial Fibrillation and Atherosclerosis	133
Thrombolysis With Tenecteplase for Minor Disabling Stroke	131
Functional Outcomes in Conservatively vs Surgically Treated Cerebellar Infarcts	131
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease	131
Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers	128
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation	125
Retinal Hemorrhage Associated with Human Granulocytic Anaplasmosis	122
N-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy	121
Error in Abstract	116
Disentangling Workflow Paradigms and Treatment Decision-making in Acute Ischemic Stroke	108
Do Neurologists Need a Goldwater Rule?	108
Histologic Anatomy of Neurocysticercosis	105
Error in Figure	104
Spontaneous AICA Dissection Presenting With Isolated Audiovestibular Loss	99
Error in Additional Contributions	99
Functional Seizures—A Critical Comorbidity Overlooked in Epilepsy Research—Reply	98
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease	96
Is It Really Itching?—Reply	95
Sleep Recording for the Diagnosis and Treatment of Paraplegia	95
Association of Cardiovascular Events With Spouse’s Subsequent Dementia	95
Error in Figure	93
Spinal Cerebrospinal Fluid Leak Mimicking a Cerebellopontine Angle Tumor	93
β-Amyloid Positron Emission Tomography Use Across Medicare Administrative Contractor Regions	93
JAMA Neurology	93
Seizure Frequency Trends Over Time in Treatment-Resistant Focal Epilepsy	91
Endovascular Stroke Thrombectomy for Patients With Large Ischemic Core	91
Risk Factors Associated With Late-Onset Epilepsy in Dementia and Mild Cognitive Impairment	91
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease	88
Role of the X Chromosome in Alzheimer Disease Genetics	87
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias	87
Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care?	87
Tackling the Unmet Therapeutic Needs in Nonsurgical Treatments for Epilepsy	84
Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke	83
Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion	82
Visual Neglect After an Isolated Lesion of the Superior Colliculus	82
Intra-Arterial Tenecteplase After Successful Reperfusion in Large Vessel Occlusion Stroke	82
Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy	82
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum	81
Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology	81
JAMA Neurology	81
JAMA Neurology	80
Error in Text	78
Perceived CTE and Suicidality—Is Perception Reality?	77
Acute Myelopathy in a Man With Cutaneous Papules	76
Error in Figures	76

Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease	75
Error in Key for Figure 3	75
Peripheral-Type Facial Paralysis and Unilateral Hemisphere Hemorrhage	74
A Rare Neurological Presentation of Kikuchi-Fujimoto Disease	73
A 62-Year-Old Man With Progressive Limb Weakness, Involuntary Movements, and HyperCKemia	73
Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	73
Functional Impairment in Individuals With Prodromal or Unrecognized Parkinson Disease	71
Magnetic Resonance Imaging Features of GABA-A Receptor Antibody-Mediated Encephalitis	71
Visualization of Parkinsonian Tongue Tremor on Ultrasonography	70
Minimally Invasive Surgery vs Medical Management Alone for Intracerebral Hemorrhage	70
AI Devices in Neurology—Moving From Diagnosis to Prognosis	69
Expanding Clinical Spectrum of Anti-GQ1b Antibody Syndrome	69
Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke	69
The New Era of Automated Electroencephalogram Interpretation	68
Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura	67
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis	66
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis	66
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome	65
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease	65
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients	64
Bibrachial Amyotrophy Due to Spontaneous Spinal Cerebrospinal Fluid Leak	63
Comparison of Perinatal Outcomes for Women With and Without Epilepsy	63
The Semont-Plus Maneuver or the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo	63
Repairing Our View of Dementia	62
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers	62
JAMA Neurology Peer Reviewers in 2021	62
Concerns Remain Regarding Ambient NO₂ Exposure and the Risk of Parkinson Disease—Reply	61
The Choreoathetotic Movement of Paroxysmal Nonkinesigenic Dyskinesia	61
Benefits and Risks of Periconceptional Folic Acid Supplementation—Reply	60
Error in Title	60
Cerebral Amyloid Angiopathy—How to Translate Updated Diagnostic Criteria for This Multifaceted Disorder to Clinical Practice?	60
Livedo Reticularis—A Presenting Sign of Neuromyelitis Optica Spectrum Disorder	60
IWG and AA Criteria—Where the Differences Matter—Reply	59
Expanding the Prion Paradigm to Include Alzheimer and Parkinson Diseases	59
Benefits and Risks of Periconceptional Folic Acid Supplementation	58
Possible Explanations for Hearing Loss in Parkinson Disease	58
Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow	58
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis	58
Adverse Childhood Experiences, Toxic Stress, and Trauma-Informed Neurology	56
Association Between Acute Myocardial Infarction and Cognition	56
Reimagining the Treatment of Distal and Medium Vessel Occlusion Strokes	55
Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest	55
Choosing the Best Antiseizure Medication—Can Artificial Intelligence Help?	55
Life Expectancy for Patients With Sporadic Creutzfeldt-Jakob Disease	55
Cognitive Behavioral Therapy for Veterans With Comorbid Posttraumatic Headache and Posttraumatic Stress Disorder Symptoms	55
Novel Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies	54
Coma Prognostication After Acute Brain Injury	54
Autism and Parkinsonism—Terminology and Confounding	51
SARS-CoV-2 Vaccination and Neuroimmunological Disease	50
Traumatic Brain Injury Recovery Trajectories in Patients With Disorders of Consciousness	49
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography	49
Addition of Nonauthor Collaborators and a Supplement	48
JAMA Neurology	48
A Woman With Eosinophilic Brainstem Meningoencephalitis	48
Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis—Variations in Real-World Experience—Reply	46
Views From Both Sides of the White Coat	46
Monogenic Stroke—Can We Overcome Nature With Nurture?	46
The Perils and Pitfalls of Global Engagement	46
How Is the X Chromosome Involved in Alzheimer Disease?	45
Chronic Immune Peripheral Nerve Myelinopathies—A Plea for Precision	45
Error in Author Affiliation	45
Errors in Figure 2 and the Short Title	45
Transcarotid Artery Revascularization for Stroke Prevention—Multiple Elephants in the Room	44
The End Justifies the Means—A Call for Nuance in the Increasing Nationwide Adoption of Stereoelectroencephalography Over Subdural Electrode Monitoring in the Surgical Evaluation of Intractable Epileps	44
Gantenerumab in Dominantly Inherited Alzheimer Disease—Reply	44
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis	43
Association Between Antiseizure Drug Monotherapy and Mortality for Patients With Poststroke Epilepsy	42
TDP-43 Accumulation Within Intramuscular Nerve Bundles of Patients With Amyotrophic Lateral Sclerosis	42
Association of Aortic Stiffness and Pressure Pulsatility With Global Amyloid-β and Regional Tau Burden Among Framingham Heart Study Participants Without Dementia	42
Exome Sequencing and the Identification of New Genes and Shared Mechanisms in Polymicrogyria	42
Visual Impairment as a Modifiable Risk Factor in Dementia Prevention and Management	42
Citius, Fortius, Altius—Understanding Which Components Drive Exercise Benefits in Parkinson Disease	41
Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors	41
GLP-1 RAs for Idiopathic Intracranial Hypertension—Time for a Trial	41
Medical Forecasting—A Skill Set Worthy of Attention	41
Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage	41
Modern Neurology Training Is Failing Outpatients	40
Structural Inequities for Historically Underserved Communities in the Adoption of Stroke Certification in the United States	40
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis	40
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease	39

Discerning the Role of Autoimmunity and Autoantibodies in Epilepsy	39
One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China	39
Statewide Emergency Medical Services Protocols for Suspected Stroke and Large Vessel Occlusion	39
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios	39
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants	39
Error in Title	38
JAMA Neurology	38
Acute Ischemic Stroke Care Quality Improvement	38
Bilateral Complete Ophthalmoplegia in a 50-Year-Old Man	38
A 51-Year-Old Woman With Abnormal Corpus Callosum Signal	37
CT Perfusion Imaging After Selection for Late-Window Endovascular Stroke Treatment	37
Error in Figures 2 and 3	37
JAMA Neurology	37
Error in Open Access Status	36
Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia	36
Multimodal Neuroimaging of Intimal Flap in a Basilar Artery Dissection	36
Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection	36
Neurologic Complications of Smallpox and Monkeypox	35
Venture Capital Investment in Neurology Companies	35
Risk Factors for Young-Onset Dementia in the UK Biobank	35
Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy	35
Risks of Expanded Medicare Coverage of Carotid Artery Stenting	35
Physical Frailty, Genetic Predisposition, and Incident Parkinson Disease	34
Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients With Large Ischemic Strokes	34
Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?	34
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels	34
Batoclimab vs Placebo for Generalized Myasthenia Gravis	33
Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal Leukoencephalopathy	33
Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants	33
Transient Focal Neurological Events in Cerebral Amyloid Angiopathy and the Long-term Risk of Intracerebral Hemorrhage and Death	33
White Matter Tract Density Index Prediction Model of Overall Survival in Glioblastoma	32
Targeting Sleep and Circadian Function in the Prevention of Alzheimer Disease	32
Genome Sequencing After Exome Sequencing in Pediatric Epilepsy	32
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease	32
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine	32
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis	32
An Acetylcholine M₁ Receptor–Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment	32
Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia	32
Multisite Skin Biopsies vs Cerebrospinal Fluid for Prion Seeding Activity in the Diagnosis of Prion Diseases	32
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease	31
Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients With Standard Surgical Risk	31
Light Reading—The Gravity of Postoperative Care	30
Paused—A Residency Interrupted	30
Error in Methods	30
E-Cigarettes and Stroke Risk—Present Uncertainties and Future Directions	30
Inducers and Cardiovascular Risk—Potential Role for Lowered Drug Exposure	30
A Funeral for a Neurologist	30
Entering Medicine as a Physician and a Patient	30
Association Between Use of Angiotensin Receptor Blockers and Incidence of Epilepsy in Patients With Hypertension—Reply	29
Remembering the Physician’s Humanity—Physicians Are Humans Too	29
Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor	28
Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers	28
Gene Therapy vs Cochlear Implantation in Restoring Hearing Function and Speech Perception for Individuals With Congenital Deafness	28
A New Dystonia Phenotype in Wilson Disease	28
Neuro-Advocacy—Professionalism in Action	28
Effect of Irrigation Fluid Temperature on Recurrence in the Evacuation of Chronic Subdural Hematoma	28
Association of Tourette Syndrome and Chronic Tic Disorder With Violent Assault and Criminal Convictions	27
Embedded Human Closed-Loop Deep Brain Stimulation for Tourette Syndrome	27
Pattern of Recurrent Nontraumatic Intracerebral Hemorrhage—Reply	27
Quality Improvement Intervention for Reducing Acute Treatment Times in Ischemic Stroke	27
Lecanemab Treatment in a Specialty Memory Clinic	27
Rethinking the Menopause Transition and Multiple Sclerosis Progression	27
What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?	27
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease—Reply	26
Error in Figure 2B	26
Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19	26
Error in Title	26
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms	26
Multiple Facial Ulcers Following a Stroke	26
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity	26
Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease	25
Error in Figures	25
Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database	25
Bilateral Calcification of the Meckel Cave Causing Hemicrania Continua	25
Gadolinium-Enhanced Aneurysm Wall Imaging and Risk of Intracranial Aneurysm Growth or Rupture	25
Trends in AVM-Associated Intracranial Hemorrhage in the United States, 2000-2019	25
Error in Figure 1	25
Iatrogenic Cerebrospinal Fluid–Venous Fistula	25
Central Retinal Artery Occlusion With Cilioretinal Artery Sparing After Semaglutide Injection	24
Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor–Inhibitor Treatment for Autoimmune Diseases	24
How SAFE Is Real-world Use of Spinal Cord Stimulation Therapy for Chronic Pain?	24
Anticoagulation in ESUS—Back From the Dead?	24
Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events	24
Combined Physiotherapy and Cognitive Behavioral Therapy for Functional Movement Disorders	24
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease	23
JAMA Neurology	23
Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage	23
Error in Title	23
Risk Factors and Prognosis of Early Posttraumatic Seizures in Moderate to Severe Traumatic Brain Injury	23
Research Criteria for the Behavioral Variant of Alzheimer Disease	23
The Cynicism of the Seronegative	22
Sex Differences in Case-Fatality Rates of Stroke—Reply	22
Aducanumab and the Business of Alzheimer Disease—Some Choice	22
Oncogenic Pathways Provide Clue to the Etiology of Human Mesial Temporal Lobe Epilepsy	22
Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups	22